Agilent Technologies Prepares for Q1 Earnings Report Amid Mixed Performance
Agilent Technologies, Inc. (A), valued at $42.1 billion, is a prominent name in life sciences, diagnostics, and applied chemical sectors. Based in Santa Clara, California, Agilent supplies advanced instruments, software, and services to various industries, including pharmaceuticals, biotechnology, and food safety. The company will announce its fiscal first-quarter earnings for 2024 after the market closes on Tuesday, February 25.
Anticipated Earnings Performance
Analysts forecast Agilent to report a profit of $1.27 per share on a diluted basis, which marks a 1.6% decrease from $1.29 per share in the equivalent quarter last year. Notably, Agilent has outperformed Wall Street’s earnings per share estimates in each of the last four quarterly reports.
Future Earnings Expectations
Looking ahead, projections for the fiscal year 2025 suggest an EPS of $5.56, reflecting a 5.1% increase from $5.29 in fiscal 2023. Further growth is expected, with an EPS estimate of $6.13 for fiscal 2026, indicating a year-over-year increase of 10.3%.
Stock Performance Overview
Over the past year, Agilent’s shares have increased by 15%, falling short of the S&P 500’s gain of 26.5%. However, its performance has outstripped the marginal increase seen with the Health Care Select Sector SPDR Fund (XLV) during the same period.
Recent Earnings Results
On November 25, Agilent’s share price saw a slight uptick following the release of its Q4 earnings. The company reported revenues of $1.7 billion and adjusted earnings of $1.46 per share, both exceeding consensus estimates, thanks in part to a 5% growth in the Agilent CrossLab Group.
Analyst Ratings and Price Targets
Analysts remain cautiously optimistic about Agilent, giving it a “Moderate Buy” rating overall. Among the 16 analysts monitoring the stock, eight have issued a “Strong Buy” recommendation, seven have maintained a “Hold” rating, and one has suggested a “Strong Sell.”
The average analyst price target for Agilent is $150.07, suggesting a potential increase of 1.8% from current levels.
On the date of publication,
Kritika Sarmah
did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data provided are solely for informational purposes. For more details, please view the Barchart Disclosure Policy
here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
